Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Medien-Archiv vom 02.06.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
02.06.Kametstal starts production of a new steel product-
02.06.Domestic product from boron mine that revolutionises the steel industry!-
02.06.The downward trend continues in the Asian scrap market-
02.06.Hoa Phat's sales increased in April-
02.06.Indonesia's steel industry aims to produce green steel-
02.06.Amendments to some laws by the Ministry of Trade-
02.06.Gerdau increases investment in digital and innovative technologies3
02.06.Mubadala becomes a partner in Tubacex's UAE unit with a $150 million investment2
02.06.Kyrgyz-Uzbek joint auto assembly plant launches trial operation-
02.06.SYNLAIT MILK LIMITED: Change in director appointed by Bright Dairy-
02.06.AFT PHARMACEUTICALS LIMITED: AFT to launch Maxigesic Rapid in the United States-
02.06.ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer150Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with...
► Artikel lesen
02.06.Nanobiotix S.A.: Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy222Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later...
► Artikel lesen
02.06.Celldex Therapeutics, Inc.: Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024118- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
► Artikel lesen
02.06.NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan624TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software availability...
► Artikel lesen
02.06.NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs117TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced new NVIDIA RTX technology to power AI assistants and digital humans running on new GeForce RTX AI laptops. NVIDIA...
► Artikel lesen
02.06.NVIDIA Supercharges Ethernet Networking for Generative AI263TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced widespread adoption of the NVIDIA Spectrum-X Ethernet networking platform as well as an accelerated product release...
► Artikel lesen
02.06.NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World's Millions of Developers Into Generative AI Developers160150+ Partners Across Every Layer of AI Ecosystem Embedding NIM Inference Microservices to Speed Enterprise AI Application Deployments From Weeks to MinutesNVIDIA Developer Program Members Gain Free...
► Artikel lesen
02.06.NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars159TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced the general availability of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans...
► Artikel lesen
02.06.Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)281Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight...
► Artikel lesen
Seite:  Weiter >>